Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06585202
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2a Open-label Study to Investigate the Safety Tolerability Pharmacokinetics Efficacy and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants with Moderate to Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis
Detailed Description:
This open-label single-arm study of ATI-2138 in moderate to severe AD participants between the ages of 18 and 60 years inclusive will investigate the safety tolerability pharmacokinetics efficacy and pharmacodynamics of ATI-2138 administered over 12 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None